In the published article, there was an error in Figure 2 as published. In this figure for the prediction and assessment of response to anti-TNFα remission-induction treatment in CD (A) a different TGFbeta pathway model version was used. The corrected Figure 2 and its caption appear below.
FIGURE 2
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
ulcerative colitis, crohn’s disease, IBD, signal transduction pathway, treatment response
Citation
Bouwman W, Verhaegh W and van de Stolpe A (2023) Corrigendum: Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity. Front. Pharmacol. 14:1183639. doi: 10.3389/fphar.2023.1183639
Received
10 March 2023
Accepted
28 March 2023
Published
05 April 2023
Volume
14 - 2023
Edited and reviewed by
Paola Patrignani, University of Studies G. d’Annunzio Chieti and Pescara, Italy
Updates
Copyright
© 2023 Bouwman, Verhaegh and van de Stolpe.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wilbert Bouwman, Wilbert.bouwman@philips.com
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.